Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not-So-Happy New Year: Device Tax Not Addressed In Fiscal Cliff Law

This article was originally published in The Pink Sheet Daily

Executive Summary

There’s no mention of a device tax delay or repeal in the measure signed by President Obama Jan. 2, and the new law contains some Medicare payment cuts as one-year “Doc Fix” pay-fors.

You may also be interested in...



Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill

The post-election, “lame-duck” Congress will face the prospect of letting massive federal spending cuts take effect and multiple tax increases kick in if it does not take action. Device firms hope to leverage the situation to repeal the looming medical device excise tax and make FDA user-fee fixes while avoiding more Medicare provider cuts.

FDA Charges Ahead With MDUFA III Implementation, Despite Budget Uncertainties

FDA has started carrying out its end of the medical device user fee agreement, with plans to issue several new guidance documents this fall, and the agency suggests that a short-term restriction on full user fee access should not inhibit its efforts.

CMS Considers Inherent Reasonableness Rule To Lower Pay For Diabetes Test Supplies

The use of a relatively obscure CMS fee-adjustment authority rather than competitive bidding to lower Medicare payment for diabetes testing supplies in the retail setting could be precedent setting.

Topics

UsernamePublicRestriction

Register

PS074861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel